WO1999058562A3 - Novel compounds - Google Patents

Novel compounds Download PDF

Info

Publication number
WO1999058562A3
WO1999058562A3 PCT/EP1999/003262 EP9903262W WO9958562A3 WO 1999058562 A3 WO1999058562 A3 WO 1999058562A3 EP 9903262 W EP9903262 W EP 9903262W WO 9958562 A3 WO9958562 A3 WO 9958562A3
Authority
WO
WIPO (PCT)
Prior art keywords
novel compounds
polypeptides
basb009
prophylactic
diagnostic
Prior art date
Application number
PCT/EP1999/003262
Other languages
French (fr)
Other versions
WO1999058562A2 (en
Inventor
Joelle Thonnard
Original Assignee
Smithkline Beecham Biolog
Joelle Thonnard
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Biolog, Joelle Thonnard filed Critical Smithkline Beecham Biolog
Priority to CA002328061A priority Critical patent/CA2328061A1/en
Priority to EP99950345A priority patent/EP1086127A1/en
Priority to AU42601/99A priority patent/AU4260199A/en
Publication of WO1999058562A2 publication Critical patent/WO1999058562A2/en
Publication of WO1999058562A3 publication Critical patent/WO1999058562A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • C07K14/212—Moraxellaceae, e.g. Acinetobacter, Moraxella, Oligella, Psychrobacter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention provides BASB009 polypeptides and polynucleotides encoding BASB009 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are diagnostic, prophylactic and therapeutic uses.
PCT/EP1999/003262 1998-05-12 1999-05-10 Novel compounds WO1999058562A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA002328061A CA2328061A1 (en) 1998-05-12 1999-05-10 Novel compounds
EP99950345A EP1086127A1 (en) 1998-05-12 1999-05-10 Novel compounds
AU42601/99A AU4260199A (en) 1998-05-12 1999-05-10 Novel compounds

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9810193.4A GB9810193D0 (en) 1998-05-12 1998-05-12 Novel compounds
GB9810193.4 1998-05-12

Publications (2)

Publication Number Publication Date
WO1999058562A2 WO1999058562A2 (en) 1999-11-18
WO1999058562A3 true WO1999058562A3 (en) 2001-05-17

Family

ID=10831938

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1999/003262 WO1999058562A2 (en) 1998-05-12 1999-05-10 Novel compounds

Country Status (5)

Country Link
EP (1) EP1086127A1 (en)
AU (1) AU4260199A (en)
CA (1) CA2328061A1 (en)
GB (1) GB9810193D0 (en)
WO (1) WO1999058562A2 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110104186A1 (en) 2004-06-24 2011-05-05 Nicholas Valiante Small molecule immunopotentiators and assays for their detection
CA2571421A1 (en) 2004-06-24 2006-01-05 Nicholas Valiante Compounds for immunopotentiation
WO2007047749A1 (en) 2005-10-18 2007-04-26 Novartis Vaccines And Diagnostics Inc. Mucosal and systemic immunizations with alphavirus replicon particles
EP2360175B1 (en) 2005-11-22 2014-07-16 Novartis Vaccines and Diagnostics, Inc. Norovirus and Sapovirus virus-like particles (VLPs)
CA2637598A1 (en) 2006-01-18 2007-02-14 University Of Chicago Compositions and methods related to staphylococcal bacterium proteins
EP2357184B1 (en) 2006-03-23 2015-02-25 Novartis AG Imidazoquinoxaline compounds as immunomodulators
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
RU2471497C2 (en) 2007-09-12 2013-01-10 Новартис Аг Mutant antigens gas57 and gas57 antibodies
CN104292312A (en) 2007-12-21 2015-01-21 诺华股份有限公司 Mutant forms of streptolysin o
WO2009111337A1 (en) 2008-03-03 2009-09-11 Irm Llc Compounds and compositions as tlr activity modulators
MX2011007456A (en) 2009-01-12 2011-08-03 Novartis Ag Cna_b domain antigens in vaccines against gram positive bacteria.
AU2010258677B2 (en) 2009-06-10 2016-10-06 Glaxosmithkline Biologicals S.A. Benzonaphthyridine-containing vaccines
ES2596653T3 (en) 2009-06-16 2017-01-11 Glaxosmithkline Biologicals Sa Opsonization bactericidal and antibody-dependent assays mediated by high-performance complement
CN102844047B (en) 2009-09-02 2017-04-05 诺华股份有限公司 Immunogenic composition containing TLR active regulators
TWI445708B (en) 2009-09-02 2014-07-21 Irm Llc Compounds and compositions as tlr activity modulators
WO2011057148A1 (en) 2009-11-05 2011-05-12 Irm Llc Compounds and compositions as tlr-7 activity modulators
AU2010339921B2 (en) 2009-12-15 2016-08-11 Glaxosmithkline Biologicals S.A. Homogeneous suspension of immunopotentiating compounds and uses thereof
EA031379B1 (en) 2010-03-23 2018-12-28 Новартис Аг Compounds (cystein based lipopeptides) and compositions as tlr2 agonists used for treating infections, inflammations, respiratory diseases etc.
JP2013532008A (en) 2010-05-28 2013-08-15 テトリス オンライン インコーポレイテッド Interactive hybrid asynchronous computer game infrastructure
US9192661B2 (en) 2010-07-06 2015-11-24 Novartis Ag Delivery of self-replicating RNA using biodegradable polymer particles
EP2950819B1 (en) 2013-02-01 2018-03-28 GlaxoSmithKline Biologicals SA Intradermal delivery of immunological compositions comprising toll-like receptor agonists
EA202091931A1 (en) 2018-02-12 2020-11-05 Иниммьюн Корпорейшн Toll-Like Receptor Ligands
US11473093B2 (en) 2020-11-04 2022-10-18 Eligo Bioscience Cutibacterium acnes recombinant phages, method of production and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995009025A1 (en) * 1993-09-29 1995-04-06 The Research Foundation Of State University Of New York VACCINE FOR $i(BRANHAMELLA CATARRHALIS)
WO1995031215A1 (en) * 1994-05-17 1995-11-23 The Research Foundation Of State University Of New York VACCINE FOR $i(MORAXELLA CATARRHALIS)
WO1997041731A1 (en) * 1996-05-03 1997-11-13 Antex Biologics, Inc. Moraxella catarrhalis outer membrane protein-106 polypeptide, gene sequence and uses thereof
WO1998006432A1 (en) * 1996-08-16 1998-02-19 The Research Foundation Of State University Of New York Outer membrane protein b1 of moraxella catarrhalis

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995009025A1 (en) * 1993-09-29 1995-04-06 The Research Foundation Of State University Of New York VACCINE FOR $i(BRANHAMELLA CATARRHALIS)
US5712118A (en) * 1993-09-29 1998-01-27 Research Foundation Of State University Of New York Vaccine for branhamella catarrhalis
WO1995031215A1 (en) * 1994-05-17 1995-11-23 The Research Foundation Of State University Of New York VACCINE FOR $i(MORAXELLA CATARRHALIS)
US5607846A (en) * 1994-05-17 1997-03-04 Research Foundation Of State University Of New York Vaccine for moraxella catarrhalis
WO1997041731A1 (en) * 1996-05-03 1997-11-13 Antex Biologics, Inc. Moraxella catarrhalis outer membrane protein-106 polypeptide, gene sequence and uses thereof
WO1998006432A1 (en) * 1996-08-16 1998-02-19 The Research Foundation Of State University Of New York Outer membrane protein b1 of moraxella catarrhalis

Also Published As

Publication number Publication date
CA2328061A1 (en) 1999-11-18
EP1086127A1 (en) 2001-03-28
AU4260199A (en) 1999-11-29
WO1999058562A2 (en) 1999-11-18
GB9810193D0 (en) 1998-07-08

Similar Documents

Publication Publication Date Title
WO1999058562A3 (en) Novel compounds
GB9810276D0 (en) Novel compounds
WO1999055873A3 (en) Basb006 polynucleotide(s) and polypeptides from neisseria meningitis
GB9820003D0 (en) Novel compounds
AU3164600A (en) Novel compounds
GB9809683D0 (en) Novel compounds
AU4504999A (en) Novel compounds
GB9810285D0 (en) Novel compounds
GB9812440D0 (en) Novel compounds
WO2002030971A3 (en) Basb205 polypeptides and polynucleotides coding therefor
AU4567300A (en) Novel compounds
WO2002034768A3 (en) Polypeptides and polynucleodides from haemophilus influenzae and their use
EP2374889A3 (en) Novel compounds
GB9918208D0 (en) Novel compounds
WO2002034772A3 (en) Novel compounds
GB0025170D0 (en) Novel compounds
WO2003010195A3 (en) Novel compounds
AU6832300A (en) Novel compounds
GB9918302D0 (en) Novel compounds
WO2002030967A3 (en) Novel compounds
AU6568800A (en) Novel compounds
WO1999058682A3 (en) Compounds from moraxella catarrhalis
WO2002046215A3 (en) Basb221 polypeptides and polynucleotides encoding basb221 polypeptides
AU6439700A (en) Novel compounds
AU1383901A (en) Novel compounds

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2328061

Country of ref document: CA

Ref country code: CA

Ref document number: 2328061

Kind code of ref document: A

Format of ref document f/p: F

NENP Non-entry into the national phase

Ref country code: KR

WWE Wipo information: entry into national phase

Ref document number: 1999950345

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1999950345

Country of ref document: EP

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 09700335

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: CA

WWW Wipo information: withdrawn in national office

Ref document number: 1999950345

Country of ref document: EP